Journal articleNat Commun2023
Increased glucose availability sensitizes pancreatic cancer to chemotherapy.
- Journal
- Nat Commun
- Published
- 28 June 2023
- Citations
- 37
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Grants 13
- IDH1 is a novel therapeutic target in pancreatic cancer F32CA247466↗
- Cognitive Impairment, Multimorbidity, and end-of-life care in older cancer patients P30CA043703↗
- Administrative Supplement P30 Cancer Center Support Grant (CCSG): Phase 1 Study of Olaparib in Combination with Durvalu… P30CA046592↗
- Community Outreach and Engagement P30CA069533↗
- Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer R01CA212600↗
- Targeting metabolic stress to induce pancreatic tumor cell death R01CA244931↗
- Stromal metabolism promotes therapeutic resistance in pancreatic cancer R01CA248160↗
- Optimizing anti-wild-type IDH1 therapy in pancreatic cancer R01CA287672↗
- MUC1-Targeted Nanotherapy for Pancreatic Cancer R21CA173605↗
- Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers R21CA263996↗
- Targeting pancreatic cancer's metabolic addiction to HuR R37CA227865↗
- Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer R37CA237421↗
- Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗